Bruno Vision Care Wins 2026 MedTech Breakthrough Award

Key Takeaways

• Deseyne lens first FDA‑cleared daily disposable EDOF contact lens.
• Study showed +0.78 diopter focus gain and 1.5‑2.2 line vision improvement.
• Targets 139 million U.S. presbyopes, potential $411 B productivity loss.
• Commercial launch slated for U.S. Q3 2026.
• Award places Bruno Vision among MedTech leaders like Alcon and Johnson & Johnson.

Pulse Analysis

Presbyopia, an age‑related loss of near‑focus affecting roughly 139 million Americans, has long been managed with multifocal glasses, progressive lenses, or invasive intra‑ocular surgeries. The market demand for a comfortable, non‑surgical solution is intense, especially as the condition is projected to impact 2.1 billion people worldwide by 2030. By introducing an Extended Depth of Focus (EDOF) design into a daily‑disposable soft lens, Bruno Vision Care addresses both visual performance and wearability, offering a novel pathway that could reshape standard care protocols for the aging population.

Deseyne’s technology hinges on Cataltheia’s patented hyper‑refractive central zone, which redistributes incoming light to create a continuous depth of focus, mitigating common multifocal drawbacks such as halos and glare. The lens material, vifilcon C, incorporates biomimetic polymers like hyaluronic acid and tamarind‑seed polysaccharide, enhancing tear‑film stability and all‑day comfort. Clinical data from a three‑site, double‑masked study demonstrated a statistically significant +0.78‑diopter increase in depth of focus and visual acuity gains of up to 2.2 lines for patients over 60, performance comparable to surgically implanted EDOF intra‑ocular lenses.

Winning the MedTech Breakthrough Award places Bruno Vision alongside industry giants such as Alcon and Johnson & Johnson, signaling strong validation from peers and investors. With a U.S. launch slated for Q3 2026, the company is poised to capture a sizable share of the presbyopia market, potentially reducing the $411 billion annual productivity loss linked to uncorrected vision. The award also underscores a broader trend toward biomimetic, AI‑enabled medical devices that prioritize patient comfort while delivering surgical‑level outcomes, setting a new benchmark for future ophthalmic innovations.